v3.19.1

Consolidated Balance Sheets Unaudited - USD ($)	Aug. 31, 2018	Feb. 28, 2018
ASSETS
Cash	$ 652	$ 697
Notes receivable, related party	235,752	235,752
Total Current Assets	236,404	236,449
Total Assets	236,404	236,449
Current Liabilities
Accounts payable and accrued liabilities	518,310	518,310
Due to related parties	742,242	277,219
Derivative liability	638,854
Current Liabilities	1,899,406	795,529
Convertible notes payable, net		415,581
Derivative liability		390,009
Total Liabilities	1,899,406	1,601,119
STOCKHOLDERS' DEFICIT
Common Stock Authorized: 990,000,000 common shares, par value of $0.001 per share Issued and outstanding: 47,571 and 34,171 common shares, respectively	48	34
Additional paid-in capital	17,921,854	17,785,335
Accumulated deficit during the development stage	(19,585,203)	(19,150,339)
Total Stockholders' Equity (Deficit)	(1,663,002)	(1,364,670)
Total Liabilities and Stockholders' Equity	236,404	236,449
Preferred Series B [Member]
STOCKHOLDERS' DEFICIT
Issued and outstanding Preferred shares	200	200
Preferred Series C [Member]
STOCKHOLDERS' DEFICIT
Issued and outstanding Preferred shares	$ 100	$ 100

Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.

Phoenix Life Sciences International Limited. 10-Q